BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shanab AA, Scully P, Crosbie O, Buckley M, O’mahony L, Shanahan F, Gazareen S, Murphy E, Quigley EMM. Small Intestinal Bacterial Overgrowth in Nonalcoholic Steatohepatitis: Association with Toll-Like Receptor 4 Expression and Plasma Levels of Interleukin 8. Dig Dis Sci 2011;56:1524-34. [DOI: 10.1007/s10620-010-1447-3] [Cited by in Crossref: 119] [Cited by in F6Publishing: 115] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Wong X, Madrid AM, Tralma K, Castillo R, Carrasco-pozo C, Navarrete P, Beltrán C, Pastene E, Gotteland M. Polyphenol extracts interfere with bacterial lipopolysaccharide in vitro and decrease postprandial endotoxemia in human volunteers. Journal of Functional Foods 2016;26:406-17. [DOI: 10.1016/j.jff.2016.08.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
2 Satoh D, Yagi T, Nagasaka T, Shinoura S, Umeda Y, Yoshida R, Utsumi M, Tanaka T, Sadamori H, Fujiwara T. CD14 upregulation as a distinct feature of non-alcoholic fatty liver disease after pancreatoduodenectomy. World J Hepatol 2013; 5(4): 189-195 [PMID: 23671723 DOI: 10.4254/wjh.v5.i4.189] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
3 Rahman K, Desai C, Iyer SS, Thorn NE, Kumar P, Liu Y, Smith T, Neish AS, Li H, Tan S, Wu P, Liu X, Yu Y, Farris AB, Nusrat A, Parkos CA, Anania FA. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. Gastroenterology. 2016;151:733-746.e12. [PMID: 27342212 DOI: 10.1053/j.gastro.2016.06.022] [Cited by in Crossref: 127] [Cited by in F6Publishing: 119] [Article Influence: 25.4] [Reference Citation Analysis]
4 Chu H, Williams B, Schnabl B. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Liver Res. 2018;2:43-51. [PMID: 30416839 DOI: 10.1016/j.livres.2017.11.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]
5 Liang Y, Zhang Y, Deng Y, Liang S, He Y, Chen Y, Liu C, Lin C, Han L, Tu G, Yang Q. Chaihu-Shugan-San Decoction Modulates Intestinal Microbe Dysbiosis and Alleviates Chronic Metabolic Inflammation in NAFLD Rats via the NLRP3 Inflammasome Pathway. Evid Based Complement Alternat Med 2018;2018:9390786. [PMID: 30105078 DOI: 10.1155/2018/9390786] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
6 Han N, Pan Z, Liu G, Yang R, Yujing B. Hypoxia: The "Invisible Pusher" of Gut Microbiota. Front Microbiol 2021;12:690600. [PMID: 34367091 DOI: 10.3389/fmicb.2021.690600] [Reference Citation Analysis]
7 Ibusuki R, Uto H, Arima S, Mawatari S, Setoguchi Y, Iwashita Y, Hashimoto S, Maeda T, Tanoue S, Kanmura S, Oketani M, Ido A, Tsubouchi H. Transgenic expression of human neutrophil peptide-1 enhances hepatic fibrosis in mice fed a choline-deficient, L-amino acid-defined diet. Liver Int. 2013;33:1549-1556. [PMID: 23682724 DOI: 10.1111/liv.12203] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
8 Ilan Y. Immune therapy for nonalcoholic steatohepatitis: are we there yet? J Clin Gastroenterol. 2013;47:298-307. [PMID: 23442833 DOI: 10.1097/mcg.0b013e31827873dc] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
9 Kjær MB, George J, Kazankov K, Grønbæk H. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy? Expert Rev Gastroenterol Hepatol 2021;15:51-64. [PMID: 32878486 DOI: 10.1080/17474124.2020.1817740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Fialho A, Fialho A, Schenone A, Thota P, McCullough A, Shen B. Association between small intestinal bacterial overgrowth and deep vein thrombosis. Gastroenterol Rep (Oxf) 2016;4:299-303. [PMID: 27044499 DOI: 10.1093/gastro/gow004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
11 Victor DW 3rd, Quigley EM. Hepatic encephalopathy involves interactions among the microbiota, gut, brain. Clin Gastroenterol Hepatol. 2014;12:1009-1011. [PMID: 24462627 DOI: 10.1016/j.cgh.2014.01.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
12 Chen B, Zhu S, Du L, He H, Kim JJ, Dai N. Reduced interstitial cells of Cajal and increased intraepithelial lymphocytes are associated with development of small intestinal bacterial overgrowth in post-infectious IBS mouse model. Scand J Gastroenterol. 2017;52:1065-1071. [PMID: 28679338 DOI: 10.1080/00365521.2017.1342141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Quigley EM, Monsour HP. The gut microbiota and the liver: implications for clinical practice. Expert Rev Gastroenterol Hepatol 2013;7:723-32. [PMID: 24134195 DOI: 10.1586/17474124.2013.848167] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
14 Fukui H. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? Diseases. 2019;7. [PMID: 31726747 DOI: 10.3390/diseases7040058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 15.5] [Reference Citation Analysis]
15 Utsunomiya H, Yamamoto Y, Takeshita E, Tokumoto Y, Tada F, Miyake T, Hirooka M, Abe M, Kumagi T, Matsuura B, Ikeda Y, Hiasa Y. Upregulated absorption of dietary palmitic acids with changes in intestinal transporters in non-alcoholic steatohepatitis (NASH). J Gastroenterol 2017;52:940-54. [PMID: 28062946 DOI: 10.1007/s00535-016-1298-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
16 Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab. 2013;24:537-545. [PMID: 23827477 DOI: 10.1016/j.tem.2013.05.009] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 13.3] [Reference Citation Analysis]
17 Wijarnpreecha K, Lou S, Watthanasuntorn K, Kroner PT, Cheungpasitporn W, Lukens FJ, Pungpapong S, Keaveny AP, Ungprasert P. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2020;32:601-8. [PMID: 31567712 DOI: 10.1097/MEG.0000000000001541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
18 Okubo H, Sakoda H, Kushiyama A, Fujishiro M, Nakatsu Y, Fukushima T, Matsunaga Y, Kamata H, Asahara T, Yoshida Y. Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. Am J Physiol Gastrointest Liver Physiol. 2013;305:G911-G918. [PMID: 24113768 DOI: 10.1152/ajpgi.00225.2013] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
19 Jiang CM, Pu CW, Hou YH, Chen Z, Alanazy M, Hebbard L. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. World J Gastroenterol 2014; 20(44): 16464-16473 [PMID: 25469014 DOI: 10.3748/wjg.v20.i44.16464] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
20 de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57:861-876. [PMID: 28875318 DOI: 10.1007/s00394-017-1524-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
21 Bohm M, Siwiec RM, Wo JM. Diagnosis and management of small intestinal bacterial overgrowth. Nutr Clin Pract. 2013;28:289-299. [PMID: 23614961 DOI: 10.1177/0884533613485882] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 7.5] [Reference Citation Analysis]
22 Duseja A, Chawla YK. Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis. 2014;18:59-71. [PMID: 24274865 DOI: 10.1016/j.cld.2013.09.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
23 Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon 2013;13:e7233. [PMID: 23885277 DOI: 10.5812/hepatmon.7233] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
24 Nakano M, Murohisa T, Imai Y, Tamano M, Hiraishi H. Association Between Appendectomy and Fibrosis Progression in Nonalcoholic Fatty Liver Disease. Gastroenterology Res 2013;6:17-25. [PMID: 27785221 DOI: 10.4021/gr513w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
25 Zhao P, Saltiel AR. From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases. J Biol Chem 2020;295:12279-89. [PMID: 32651233 DOI: 10.1074/jbc.REV120.011356] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 19.0] [Reference Citation Analysis]
26 Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol 2021;36:1497-507. [PMID: 33217052 DOI: 10.1111/jgh.15353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 de Medeiros IC, de Lima JG. Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease? – A mechanistic hypothesis. Medical Hypotheses 2015;85:148-52. [DOI: 10.1016/j.mehy.2015.04.021] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
28 Bakhshimoghaddam F, Alizadeh M. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. Clin Nutr ESPEN 2021;44:61-8. [PMID: 34330514 DOI: 10.1016/j.clnesp.2021.05.012] [Reference Citation Analysis]
29 Ghoshal UC, Goel A, Quigley EMM. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm. Indian J Gastroenterol 2020;39:9-21. [PMID: 32291578 DOI: 10.1007/s12664-020-01027-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
30 Ricci JER Júnior, Chebli LA, Ribeiro TCDR, Castro ACS, Gaburri PD, Pace FHDL, Barbosa KVBD, Ferreira LEVVDC, Passos MDCF, Malaguti C, Delgado ÁHDA, Campos JD, Coelho AR, Chebli JMF. Small-Intestinal Bacterial Overgrowth is Associated With Concurrent Intestinal Inflammation But Not With Systemic Inflammation in Crohn's Disease Patients. J Clin Gastroenterol 2018;52:530-6. [PMID: 28134633 DOI: 10.1097/MCG.0000000000000803] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
31 Li J, Sapper TN, Mah E, Moller MV, Kim JB, Chitchumroonchokchai C, McDonald JD, Bruno RS. Green tea extract treatment reduces NFκB activation in mice with diet-induced nonalcoholic steatohepatitis by lowering TNFR1 and TLR4 expression and ligand availability. J Nutr Biochem 2017;41:34-41. [PMID: 28038359 DOI: 10.1016/j.jnutbio.2016.12.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
32 Sharifnia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, Peek RM, Abumrad NN, Flynn CR. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015;309:G270-G278. [PMID: 26113297 DOI: 10.1152/ajpgi.00304.2014] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 18.3] [Reference Citation Analysis]
33 Campo L, Eiseler S, Apfel T, Pyrsopoulos N. Fatty Liver Disease and Gut Microbiota: A Comprehensive Update. J Clin Transl Hepatol. 2019;7:56-60. [PMID: 30944821 DOI: 10.14218/jcth.2018.00008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 6.3] [Reference Citation Analysis]
34 Srivastava D, Ghoshal U, Mittal RD, Ghoshal UC. Associations between IL-1RA polymorphisms and small intestinal bacterial overgrowth among patients with irritable bowel syndrome from India. Neurogastroenterol Motil. 2014;26:1408-1416. [PMID: 25073651 DOI: 10.1111/nmo.12399] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
35 Lee HJ, Yeon JE, Ko EJ, Yoon EL, Suh SJ, Kang K, Kim HR, Kang SH, Yoo YJ, Je J, Lee BJ, Kim JH, Seo YS, Yim HJ, Byun KS. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21(45): 12787-12799 [PMID: 26668503 DOI: 10.3748/wjg.v21.i45.12787] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
36 Fukui H. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? Inflamm Intest Dis. 2016;1:135-145. [PMID: 29922669 DOI: 10.1159/000447252.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Rafiei R, Bemanian M, Rafiei F, Bahrami M, Fooladi L, Ebrahimi G, Hemmat A, Torabi Z. Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth. Rom J Intern Med 2018;56:85-9. [PMID: 29101772 DOI: 10.1515/rjim-2017-0042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
38 Daulatzai MA. Chronic functional bowel syndrome enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia. Neurochem Res 2014;39:624-44. [PMID: 24590859 DOI: 10.1007/s11064-014-1266-6] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 10.3] [Reference Citation Analysis]
39 Zhang M, Zhu HM, He F, Li BY, Li XC. Association between acute pancreatitis and small intestinal bacterial overgrowth assessed by hydrogen breath test. World J Gastroenterol 2017; 23(48): 8591-8596 [PMID: 29358867 DOI: 10.3748/wjg.v23.i48.8591] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
40 Boursier J, Diehl AM. Nonalcoholic Fatty Liver Disease and the Gut Microbiome. Clin Liver Dis 2016;20:263-75. [PMID: 27063268 DOI: 10.1016/j.cld.2015.10.012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 8.3] [Reference Citation Analysis]
41 Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari Mde L, Vilela EG, Torres HO, Cunha AS, Ferrari TC. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016;8:E397. [PMID: 27367724 DOI: 10.3390/nu8070397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
42 Frasinariu OE, Ceccarelli S, Alisi A, Moraru E, Nobili V. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis. 2013;45:543-551. [PMID: 23280158 DOI: 10.1016/j.dld.2012.11.010] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 6.6] [Reference Citation Analysis]
43 Mikolasevic I, Delija B, Mijic A, Stevanovic T, Skenderevic N, Sosa I, Krznaric-Zrnic I, Abram M, Krznaric Z, Domislovic V, Filipec Kanizaj T, Radic-Kristo D, Cubranic A, Grubesic A, Nakov R, Skrobonja I, Stimac D, Hauser G. Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease diagnosed by transient elastography and liver biopsy. Int J Clin Pract 2021;75:e13947. [PMID: 33406286 DOI: 10.1111/ijcp.13947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 王海昆, 杨涛, 姚萍. NAFLD家兔肠道菌群与肠黏膜Toll样受体4的关系. 世界华人消化杂志 2013; 21(35): 3988-3993 [DOI: 10.11569/wcjd.v21.i35.3988] [Reference Citation Analysis]
45 王丽, 李显辉. 益生菌对大鼠非酒精性脂肪肝的治疗作用及机制. 世界华人消化杂志 2013; 21(36): 4127-4132 [DOI: 10.11569/wcjd.v21.i36.4127] [Reference Citation Analysis]
46 Wang Q, Wang B, Saxena V, Miles L, Tiao J, Mortensen JE, Nathan JD. The gut-liver axis: impact of a mouse model of small-bowel bacterial overgrowth. J Surg Res 2018;221:246-56. [PMID: 29229136 DOI: 10.1016/j.jss.2017.08.049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
47 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 30.0] [Reference Citation Analysis]
48 Dornas W, Lagente V. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis. Pharmacol Res. 2019;141:418-428. [PMID: 30658094 DOI: 10.1016/j.phrs.2019.01.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
49 Ishida RK, Faintuch J, Ribeiro AS, Ribeiro U, Cecconello I. Asymptomatic gastric bacterial overgrowth after bariatric surgery: are long-term metabolic consequences possible? Obes Surg. 2014;24:1856-1861. [PMID: 24817372 DOI: 10.1007/s11695-014-1277-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
50 Li DY, Yang M, Edwards S, Ye SQ. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota? JPEN J Parenter Enteral Nutr. 2013;37:787-793. [PMID: 23538296 DOI: 10.1177/0148607113481623] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
51 Sawada K, Ohtake T, Hasebe T, Abe M, Tanaka H, Ikuta K, Suzuki Y, Fujiya M, Hasebe C, Kohgo Y. Augmented hepatic Toll-like receptors by fatty acids trigger the pro-inflammatory state of non-alcoholic fatty liver disease in mice: FAs make the pro-inflammatory state of NAFLD. Hepatol Res 2014;44:920-34. [DOI: 10.1111/hepr.12199] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
52 Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract. 2011;26:565-576. [PMID: 21947639 DOI: 10.1177/0884533611419668] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 7.6] [Reference Citation Analysis]
53 Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. World J Hepatol 2017; 9(11): 533-543 [PMID: 28469809 DOI: 10.4254/wjh.v9.i11.533] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 19.8] [Reference Citation Analysis]
54 Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr 2020;14:1875-87. [PMID: 32998095 DOI: 10.1016/j.dsx.2020.09.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
55 Fukui H. Gut Microbiota and Host Reaction in Liver Diseases. Microorganisms. 2015;3:759-791. [PMID: 27682116 DOI: 10.3390/microorganisms3040759] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
56 Lebeaupin C, Proics E, de Bieville CH, Rousseau D, Bonnafous S, Patouraux S, Adam G, Lavallard VJ, Rovere C, Le Thuc O, Saint-Paul MC, Anty R, Schneck AS, Iannelli A, Gugenheim J, Tran A, Gual P, Bailly-Maitre B. ER stress induces NLRP3 inflammasome activation and hepatocyte death. Cell Death Dis 2015;6:e1879. [PMID: 26355342 DOI: 10.1038/cddis.2015.248] [Cited by in Crossref: 162] [Cited by in F6Publishing: 162] [Article Influence: 27.0] [Reference Citation Analysis]
57 Wang C, Zhu C, Shao L, Ye J, Shen Y, Ren Y. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. Mediators Inflamm. 2019;2019:7659509. [PMID: 31341422 DOI: 10.1155/2019/7659509] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
58 Cheng X, Zhang L, Xie NC, Xu HL, Lian YJ. Association between small-intestinal bacterial overgrowth and deep vein thrombosis in patients with spinal cord injuries. J Thromb Haemost 2017;15:304-11. [PMID: 27930853 DOI: 10.1111/jth.13583] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
59 Ilan Y. Leaky gut and the liver: A role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol 2012; 18(21): 2609-2618 [PMID: 22690069 DOI: 10.3748/wjg.v18.i21.2609] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 104] [Article Influence: 12.4] [Reference Citation Analysis]
60 Guimarães VM, Santos VN, Borges PSDA, De Farias JLR, Grillo P, Parise ER. PERIPHERAL BLOOD ENDOTOXIN LEVELS ARE NOT ASSOCIATED WITH SMALL INTESTINAL BACTERIAL OVERGROWTH IN NONALCOHOLIC FATTY LIVER DISEASE WITHOUT CIRRHOSIS. Arq Gastroenterol 2020;57:471-6. [DOI: 10.1590/s0004-2803.202000000-82] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Sharifnia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, Peek RM, Abumrad NN, Flynn CR. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015;309:G270-G278. [PMID: 26113297 DOI: 10.1152/ajpgi.00304.2014.Epub] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Aragonès G, González-García S, Aguilar C, Richart C, Auguet T. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:8507583. [PMID: 30719448 DOI: 10.1155/2019/8507583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
63 Kitabatake H, Tanaka N, Fujimori N, Komatsu M, Okubo A, Kakegawa K, Kimura T, Sugiura A, Yamazaki T, Shibata S, Ichikawa Y, Joshita S, Umemura T, Matsumoto A, Koinuma M, Sano K, Aoyama T, Tanaka E. Association between endotoxemia and histological features of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(4): 712-722 [PMID: 28216979 DOI: 10.3748/wjg.v23.i4.712] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
64 Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype. World J Gastroenterol 2014; 20(10): 2482-2491 [PMID: 24627585 DOI: 10.3748/wjg.v20.i10.2482] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 53] [Article Influence: 8.3] [Reference Citation Analysis]
65 Grabherr F, Grander C, Effenberger M, Adolph TE, Tilg H. Gut Dysfunction and Non-alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne). 2019;10:611. [PMID: 31555219 DOI: 10.3389/fendo.2019.00611] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
66 Noureddin M, Muthiah MD, Sanyal AJ. Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00105. [PMID: 33102791 DOI: 10.1002/edm2.105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
67 Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, Ray P, Dhiman RK, Chawla Y. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016;31:213-221. [PMID: 26212089 DOI: 10.1111/jgh.13058] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 14.0] [Reference Citation Analysis]
68 You N, Xu J, Wang L, Zhuo L, Zhou J, Song Y, Ali A, Luo Y, Yang J, Yang W, Zheng M, Xu J, Shao L, Shi J. Fecal Fungi Dysbiosis in Nonalcoholic Fatty Liver Disease. Obesity (Silver Spring) 2021;29:350-8. [PMID: 33491316 DOI: 10.1002/oby.23073] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Giron F, Quigley EMM. Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective. J Neurogastroenterol Motil 2018;24:355-66. [PMID: 29684976 DOI: 10.5056/jnm18004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
70 de Barros F, Fonseca ABM. Bariatric surgery during the evolution of fatty liver-A randomized clinical trial comparing gastric bypass and sleeve gastrectomy based on transient elastography. Clin Obes 2020;10:e12393. [PMID: 32885600 DOI: 10.1111/cob.12393] [Reference Citation Analysis]
71 Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1525. [PMID: 32102237 DOI: 10.3390/ijms21041525] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
72 Yamamoto K, Ikeya T, Okuyama S, Fukuda K, Kobayashi D. The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development. J Gastroenterol Hepatol 2021;36:1971-8. [PMID: 33201570 DOI: 10.1111/jgh.15350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Duarte SMB, Stefano JT, Oliveira CP. Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Ann Hepatol 2019;18:416-21. [PMID: 31036494 DOI: 10.1016/j.aohep.2019.04.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
74 Parekh PJ, Balart LA, Johnson DA. The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease. Clin Transl Gastroenterol 2015;6:e91. [PMID: 26087059 DOI: 10.1038/ctg.2015.16] [Cited by in Crossref: 119] [Cited by in F6Publishing: 106] [Article Influence: 19.8] [Reference Citation Analysis]
75 Quigley EM, Stanton C, Murphy EF. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol. 2013;58:1020-1027. [PMID: 23183530 DOI: 10.1016/j.jhep.2012.11.023] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 8.3] [Reference Citation Analysis]
76 Kessoku T, Kobayashi T, Tanaka K, Yamamoto A, Takahashi K, Iwaki M, Ozaki A, Kasai Y, Nogami A, Honda Y, Ogawa Y, Kato S, Imajo K, Higurashi T, Hosono K, Yoneda M, Usuda H, Wada K, Saito S, Nakajima A. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. Int J Mol Sci 2021;22:8161. [PMID: 34360923 DOI: 10.3390/ijms22158161] [Reference Citation Analysis]
77 Bibbò S, Ianiro G, Dore MP, Simonelli C, Newton EE, Cammarota G. Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease. Mediators Inflamm 2018;2018:9321643. [PMID: 29563854 DOI: 10.1155/2018/9321643] [Cited by in Crossref: 20] [Cited by in F6Publishing: 30] [Article Influence: 6.7] [Reference Citation Analysis]
78 Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:691-701. [PMID: 21045794 DOI: 10.1038/nrgastro.2010.172] [Cited by in Crossref: 298] [Cited by in F6Publishing: 273] [Article Influence: 27.1] [Reference Citation Analysis]
79 Suriano F, Neyrinck AM, Verspreet J, Olivares M, Leclercq S, Van de Wiele T, Courtin CM, Cani PD, Bindels LB, Delzenne NM. Particle size determines the anti-inflammatory effect of wheat bran in a model of fructose over-consumption: Implication of the gut microbiota. Journal of Functional Foods 2018;41:155-62. [DOI: 10.1016/j.jff.2017.12.035] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 5.7] [Reference Citation Analysis]
80 Fitriakusumah Y, Lesmana CRA, Bastian WP, Jasirwan COM, Hasan I, Simadibrata M, Kurniawan J, Sulaiman AS, Gani RA. The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience. BMC Gastroenterol 2019;19:43. [PMID: 30894137 DOI: 10.1186/s12876-019-0960-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
81 Okubo H, Kushiyama A, Sakoda H, Nakatsu Y, Iizuka M, Taki N, Fujishiro M, Fukushima T, Kamata H, Nagamachi A, Inaba T, Nishimura F, Katagiri H, Asahara T, Yoshida Y, Chonan O, Encinas J, Asano T. Involvement of resistin-like molecule β in the development of methionine-choline deficient diet-induced non-alcoholic steatohepatitis in mice. Sci Rep 2016;6:20157. [PMID: 26818807 DOI: 10.1038/srep20157] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
82 Coelho LK, Carvalho NS, Navarro-Rodriguez T, Marson FAL, Carvalho PJPC. Lactulose Breath Testing Can Be a Positive Predictor Before Weight Gain in Participants with Obesity Submitted to Roux-en-Y Gastric Bypass. Obes Surg 2019;29:3457-64. [PMID: 31187458 DOI: 10.1007/s11695-019-04006-z] [Reference Citation Analysis]
83 Fialho A, Fialho A, Kochhar G, Schenone AL, Thota P, McCullough AJ, Shen B. Association Between Small Intestinal Bacterial Overgrowth by Glucose Breath Test and Coronary Artery Disease. Dig Dis Sci 2018;63:412-21. [PMID: 29110161 DOI: 10.1007/s10620-017-4828-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
84 Ponziani FR, Pecere S, Gasbarrini A, Ojetti V. Physiology and pathophysiology of liver lipid metabolism. Expert Review of Gastroenterology & Hepatology 2015;9:1055-67. [DOI: 10.1586/17474124.2015.1056156] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
85 Liu Q, Liu S, Chen L, Zhao Z, Du S, Dong Q, Xin Y, Xuan S. Role and effective therapeutic target of gut microbiota in NAFLD/NASH. Exp Ther Med 2019;18:1935-44. [PMID: 31410156 DOI: 10.3892/etm.2019.7781] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
86 Ceccarelli S, Panera N, Mina M, Gnani D, De Stefanis C, Crudele A, Rychlicki C, Petrini S, Bruscalupi G, Agostinelli L, Stronati L, Cucchiara S, Musso G, Furlanello C, Svegliati-Baroni G, Nobili V, Alisi A. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. Oncotarget 2015;6:41434-52. [PMID: 26573228 DOI: 10.18632/oncotarget.5163] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 12.4] [Reference Citation Analysis]
87 Zhou X, Han D, Xu R, Wu H, Qu C, Wang F, Wang X, Zhao Y. Glycine protects against high sucrose and high fat-induced non-alcoholic steatohepatitis in rats. Oncotarget 2016;7:80223-37. [PMID: 27784003 DOI: 10.18632/oncotarget.12831] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
88 Lichota A, Gwozdzinski K, Szewczyk EM. Microbial Modulation of Coagulation Disorders in Venous Thromboembolism. J Inflamm Res 2020;13:387-400. [PMID: 32801832 DOI: 10.2147/JIR.S258839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
89 Potoupni V, Georgiadou M, Chatzigriva E, Polychronidou G, Markou E, Zapantis Gakis C, Filimidou I, Karagianni M, Anastasilakis D, Evripidou K, Ftergioti A, Togkaridou M, Tsaftaridis N, Apostolopoulos A, Polyzos SA. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34289181 DOI: 10.1111/jgh.15631] [Reference Citation Analysis]
90 Gkolfakis P, Dimitriadis G, Triantafyllou K. Gut microbiota and non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2015;14:572-81. [PMID: 26663004 DOI: 10.1016/s1499-3872(15)60026-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 22] [Article Influence: 8.8] [Reference Citation Analysis]
91 Ohtani N, Hara E. Gut-liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota. Cancer Sci 2021. [PMID: 34533882 DOI: 10.1111/cas.15142] [Reference Citation Analysis]
92 Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y, Kato S, Mawatari H, Shibata W, Kitani H, Ikejima K, Kirikoshi H, Nakajima N, Saito S, Maeyama S, Watanabe S, Wada K, Nakajima A. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab 2012;16:44-54. [PMID: 22768838 DOI: 10.1016/j.cmet.2012.05.012] [Cited by in Crossref: 194] [Cited by in F6Publishing: 184] [Article Influence: 21.6] [Reference Citation Analysis]
93 Fukui H. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? Inflamm Intest Dis 2016;1:135-45. [PMID: 29922669 DOI: 10.1159/000447252] [Cited by in Crossref: 110] [Cited by in F6Publishing: 101] [Article Influence: 22.0] [Reference Citation Analysis]
94 Chedid V, Dhalla S, Clarke JO, Roland BC, Dunbar KB, Koh J, Justino E, Tomakin E, Mullin GE. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med 2014;3:16-24. [PMID: 24891990 DOI: 10.7453/gahmj.2014.019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
95 Chong CYL, Orr D, Plank LD, Vatanen T, O'Sullivan JM, Murphy R. Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12:E937. [PMID: 32230987 DOI: 10.3390/nu12040937] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
96 Aqel B, DiBaise JK. Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. Nutr Clin Pract 2015;30:780-6. [PMID: 26449892 DOI: 10.1177/0884533615605811] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
97 Norris GH, Blesso CN. Dietary sphingolipids: potential for management of dyslipidemia and nonalcoholic fatty liver disease. Nutr Rev 2017;75:274-85. [PMID: 28383715 DOI: 10.1093/nutrit/nux004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
98 Hodges JK, Sasaki GY, Bruno RS. Anti-inflammatory activities of green tea catechins along the gut-liver axis in nonalcoholic fatty liver disease: lessons learned from preclinical and human studies. J Nutr Biochem 2020;85:108478. [PMID: 32801031 DOI: 10.1016/j.jnutbio.2020.108478] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
99 Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17:481. [PMID: 27043550 DOI: 10.3390/ijms17040481] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
100 Scalera A, Di Minno MND, Tarantino G. What does irritable bowel syndrome share with non-alcoholic fatty liver disease? World J Gastroenterol 2013; 19(33): 5402-5420 [PMID: 24023483 DOI: 10.3748/wjg.v19.i33.5402] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
101 Miazga A, Osiński M, Cichy W, Żaba R. Current views on the etiopathogenesis, clinical manifestation, diagnostics, treatment and correlation with other nosological entities of SIBO. Adv Med Sci 2015;60:118-24. [PMID: 25657082 DOI: 10.1016/j.advms.2014.09.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
102 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients. 2014;6:5583-5599. [PMID: 25479248 DOI: 10.3390/nu6125583] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
103 Guo Y, Ding PH, Liu LJ, Shi L, Mao TY, Li JX, Wang YL. Gegen Qinlian Decoction Attenuates High-Fat Diet-Induced Steatohepatitis in Rats via Gut Microbiota. Evid Based Complement Alternat Med 2018;2018:7370891. [PMID: 30671129 DOI: 10.1155/2018/7370891] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
104 关月, 曹伟军, 张振玉. 肠道微生态与非酒精性脂肪性肝病的相关性研究现状及临床意义. 世界华人消化杂志 2015; 23(36): 5797-5802 [DOI: 10.11569/wcjd.v23.i36.5797] [Reference Citation Analysis]
105 Fialho A, Fialho A, Thota P, McCullough A, Shen B. Higher visceral to subcutaneous fat ratio is associated with small intestinal bacterial overgrowth. Nutr Metab Cardiovasc Dis 2016;26:773-7. [PMID: 27282099 DOI: 10.1016/j.numecd.2016.04.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
106 Arslan N. Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol 2014; 20(44): 16452-16463 [PMID: 25469013 DOI: 10.3748/wjg.v20.i44.16452] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 79] [Article Influence: 13.1] [Reference Citation Analysis]
107 Dattaroy D, Seth RK, Das S, Alhasson F, Chandrashekaran V, Michelotti G, Fan D, Nagarkatti M, Nagarkatti P, Diehl AM, Chatterjee S. Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation. Am J Physiol Gastrointest Liver Physiol. 2016;310:G510-G525. [PMID: 26718771 DOI: 10.1152/ajpgi.00259.2015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
108 Della Corte C, Liccardo D, Ferrari F, Alisi A, Nobili V. Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 2014;15:2501-11. [DOI: 10.1517/14656566.2014.960389] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
109 Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;50:628-639. [PMID: 31373710 DOI: 10.1111/apt.15416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
110 Li J, Sapper TN, Mah E, Rudraiah S, Schill KE, Chitchumroonchokchai C, Moller MV, McDonald JD, Rohrer PR, Manautou JE, Bruno RS. Green tea extract provides extensive Nrf2-independent protection against lipid accumulation and NFκB pro- inflammatory responses during nonalcoholic steatohepatitis in mice fed a high-fat diet. Mol Nutr Food Res 2016;60:858-70. [PMID: 26679056 DOI: 10.1002/mnfr.201500814] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 8.4] [Reference Citation Analysis]
111 Jo JH, Park SJ, Cheon JH, Kim TI, Kim WH. Rediscover the clinical value of small intestinal bacterial overgrowth in patients with intestinal Behçet's disease. J Gastroenterol Hepatol 2018;33:375-9. [PMID: 28666309 DOI: 10.1111/jgh.13855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 唐外姣, 周本杰. 肠道菌群失调--非酒精性脂肪肝病治疗新靶点. 世界华人消化杂志 2017; 25(22): 2000-2006 [DOI: 10.11569/wcjd.v25.i22.2000] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
113 Ogawa Y, Imajo K, Honda Y, Kessoku T, Tomeno W, Kato S, Fujita K, Yoneda M, Saito S, Saigusa Y, Hyogo H, Sumida Y, Itoh Y, Eguchi K, Yamanaka T, Wada K, Nakajima A. Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin. Sci Rep 2018;8:11365. [PMID: 30054551 DOI: 10.1038/s41598-018-29735-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
114 Quesada-Vázquez S, Aragonès G, Del Bas JM, Escoté X. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis. Cells 2020;9:E176. [PMID: 31936799 DOI: 10.3390/cells9010176] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 19.0] [Reference Citation Analysis]
115 Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World J Gastroenterol 2014; 20(43): 16079-16094 [PMID: 25473159 DOI: 10.3748/wjg.v20.i43.16079] [Cited by in CrossRef: 236] [Cited by in F6Publishing: 193] [Article Influence: 33.7] [Reference Citation Analysis]